Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lexaria Enters Definitive License Agreement with California Cannabis Beverage Manufacturer
KELOWNA, BC / ACCESSWIRE / April 25, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with GP Holdings LLC. ("GP") whereby Lexaria is providing its patented DehydraTECHTM technology to empower next-generation performance in high absorption, fast-acting cannabis-infused beverages to be developed and sold in California.
GP is establishing its operation as the leading THC beverage contract manufacturer in the state of California and expects the commencement of operations from its new state-of-the-art bottling facility within the next two quarters. Lexaria and GP have been collaborating for months to develop the highest performing cannabis beverages available anywhere, with nearly zero unwanted cannabis odor or flavor, and complete clarity and transparency of even sparkling beverages. More info about GP can be found at www.growpacker.com
GP has acquired 5-year semi-exclusive rights to use Lexaria's DehydraTECHTM technology for beverage applications within California for an undisclosed sum and a royalty on revenue generated on products sold utilizing DehyrdaTECHTM. In addition, GP also intends to develop topical skin products using the technology and has also acquired matching rights for this application.
The California cannabis-beverage market is expected to be one of the largest edible product segments, and this agreement continues Lexaria's progress of building an international ecosystem empowering licensed producers of all sizes with the ability to create best-of-class sector leaders. Under the terms of the semi-exclusive Agreement, Lexaria can offer other licensee partners the option of utilizing GP’s formulation and manufacturing expertise to produce cannabis-infused, DehydraTECH™-powered beverages and topicals throughout the state of California.
"The use of DehydraTECHTM triggers a race to the top in the California THC beverage and topicals market through this 5-year license agreement," said Chief Executive Officer Chris Bunka. "This is another long-term strategic relationship that will give consumers the faster acting and highly potent products they deserve, and class-leading flavor profiles for the beverage segment in particular."
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook http://tinyurl.com/y8vzcaam
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
Good comeback off the bottom. As per the video Chris says "maybe" profitability by year end. Not reassuring with talks with over 20 companies and several outstanding LOI's from over a year ago.
Been long this since 10 cents and sold most of mine in the $2 range Canadian. Will wait this one out til they put out some real revenue numbers. Too much mystery still on how these edible deals are structured per sales. Without something substantial it could take another big hit next week if pot stocks keep flushing out.
We need some solid news on LOI's becoming MOU's or new deals to keep this price up. Patents are great but need to show the pot/pharma market wants it.
Canadian volume half of the US. Agreed, with TD and RBC down must be letting shorts to mess with us again. Could bounce back hard like many did yesterday after TD started back up.
Bouncing back from the fishing trip. I like the narrow range trading, positive signs.
Something could be in the works but not finalized. Where's there's smoke, there's fire. Well overdue on all those LOI's converting to MOU's.
Love the smell of big news coming. $$$$
Rock and roll time! We got some mojo goin on here finally. Bunka's statements of us getting market credibility has kicked in at long last.
Let's get a bidding war going between the big boys. I say $2 and Bunka would take it with his 20 million shares. Everyone has their price.
The shorts will clearly be worrying about their shorts. Great digging presley! This smells like a new symbol in the US or a possible relisting ?
Agree on the Canadian base, as per cash flow laws too. It takes away the crazy a$$ Sessions risk they do something really archaic and protects shareholders is the way I see it.
Shorty's on the run. He's going to get crucified as Lexaria delivers us the goods.
Did you all get the Vegas update yesterday from the company ? Verified what I heard. Wanting to do deals right on the floor? Wow.
Couple of key parts.
"Lexaria Bioscience sent a full team to Las Vegas for this year’s MJBizCon where more than 18,000 people networked advanced the cannabis business agenda. The Lexaria booth was packed for most of this 3-day event, and while the crowds that were at times 3-deep were flattering to experience, at times this led to delays. We spoke with hundreds of people and discussed so many stories. Listening to you talk about how cannabidiol (CBD) has impacted your life delivered more than a couple of emotional moments and we at Lexaria are truly honored that you’ve chosen to share such deeply personal experiences with us."
"Manufacturers at times indicated their desire to “do a deal” with us right on the conference floor. Everyone is talking about growing demand in general and new demand in particular, for both non-psychoactive products as well as for cannabis products in general with improved attributes. As a result of the increased demand for business discussions, Lexaria is expanding its sales team and infrastructure."
You're welcome BMoney. Good move Presley, but I wouldn't want to be caught on the outside when big news starts rolling out. Lexaria is finally starting to get credibility in the marketplace. Just one confirmed deal will start the ball rolling well over $1 US.
They had so much traffic at their Vegas booth they were overwhelmed. Lexaria is on the radars of many deep pockets looking for a pullback here. I'm one of them and never sold a share yet. I smell a deal soon as the LOI's clamber to close MOU's.
Canuck side holding up well, down a penny as the US side down 6 cents and moves it down 3 cents on 500 shares. Go figger.
They should halt the stock for some news and really make the shorts sweat it.
Looks like a $2 stock to me. Shorters can suck on it,as it's only going to get worse for you. Cover now or be screwed.
New highs coming. Those dumping like last time it hit 90's will be one sorry a$$.
Bunka won't be selling a share. He knows this is major buyout target at 10 times todays price. Boogie on Lexies !!
Who let the dogs out ??? Beauty close of 75 cents on the Canadian side. Booyah !!!
Maybe more in the AM ?
Smells like big news to me. Bring it on !
I would think you are bang on presley.
Way better website. Now looks like professional biotech versus the kinda fake looking healthy living style.
The LOI's are waiting for the test results to sign I would bet. Once they prove it, (which I'm confident they will) this will continue its ascent to $1 plus as the deals roll in.
With 4 million warrants in the money this is going to need some big news to take them all out. Some pharma deals will do it.
If they are in talks with 4 pharma companies and planning on multiple deals then forget the pot edibles angle for the time being. This is going bigtime where the real monster money is. Pharmaceuticals.
You must have wrote them shorty and they didn't work. Bummer you have to cover.
Shorty don't get that $4 million buys you a lot of promo to move the stock when the time is right.
Obviously not bright enough to see the stock has bottomed and his short is up shit creek.
Give it up shorty. IR guys always get big options/warrants because they can be fired tomorrow if they don't produce. More short scare bullshit.
If the stock goes down how much does the guy get ? It's not $300K either and if he gets the stock over $1 by bringing in large investors then good on him and us.
Going short at the bottom must be a painful existance. Calling Chris crooked is a recipe for defamation as well.
Great IR guy, after being in the bizz since 94 he will have a huge Rolodex of contacts in the US as well as Canada.
I expect to see some money move in here soon and painfully squeeze out the scat short scumbags.
Must be waiting on the last of the warrant dumpers,announcement of NRC testing starting and revenue news. This is what happens when you desperately needed money a year ago with all the cheap financings. They always come back to haunt you until the next leg of news cleans them out for good.
Lexaria Appoints New Acting CFO
Vancouver, British Columbia / TheNewswire / June 5, 2017 – Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) is pleased to announce that its has appointed Allan Spissinger as new acting CFO, Secretary and Treasurer.
Allan Spissinger was involved in the information technologies (IT) sector for more than 10 years working on corporate IT infrastructure and software development projects before focusing on finance and accounting. Allan joined the audit and assurance practice of PricewaterouseCoopers (PwC) obtaining his Chartered Professional Accountant (CPA) designation by working primarily in the public company space on financial reporting and Sarbanes-Oxley (SOX) compliance in sectors including resources, manufacturing and technologies.
Allan has managed private businesses for 20 years before joining Lexaria in September 2014 as its corporate controller and is intimately familiar with its operations, procedures and controls. “Working with the Lexaria management team has been an inspirational experience,” said Mr. Spissinger. “I look forward to my expanding role and continuing to build the exciting future that Lexaria's patented technologies enable.”
Lexaria’s CEO Chris Bunka says, “Everyone at Lexaria welcomes Allan in his new role as CFO as we continue to strengthen our leadership team. I have every confidence in Allan and his abilities to help guide Lexaria through what we expect to be a period of phenomenal growth to come.”
Separately, the Company announces it has received US$1,540 for the exercise of 11,000 existing warrants prices at US$0.14. The Company has also settled debt of US$12,000 through the issuance of 35,294 shares at a deemed price of US$0.34. 200,000 stock options have been granted to Mr. Spissinger with an exercise price of US$0.37. No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Lexaria has 18 patents pending and patent applications filed in more than 40 countries worldwide.
Let's hope it's that.
New round of warrant dumpers, this could get ugly.
They don't use Lexaria's name at this point due to competitive reasons at the request of the company from what I understand. This could get interesting from a revenue point as they expand into California.
Over 900,000 shorts now. Throw us some big revenue news and squeeze these mofos.
Agreed but with every promo to those who have never heard of Lexaria a certain percentage will be loyal holders. It's a crowded space and we haven't had a serious promo since January.
Most pot stocks with high share prices that don't make sense to us have very high promo budgets in the $500K range. We spent like $25K ? You get what you pay for.